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Restricted universal guidelines for ROP screening: A possible
misguidance for middle income countries
Ömer ERDEVE1, Begüm ATASAY1, Saadet ARSAN1, Figen BATUOĞLU2,
Huban ATİLLA2, Tomris TÜRMEN1

Aim: The objective of all studies evaluating retinopathy of prematurity (ROP) screening criteria has been to minimize
the number of infants screened while missing no patients with ROP who required treatment. Studies supporting the
recommendation that screening for ROP could be restricted to infants born at less than 30 weeks of gestation with birth
weights of less than 1250 g have been reported recently, especially from Western countries. However, with the lack of local
outcome data, application of the new restricted screening guidelines to infants in middle income countries may lead to
misguidance. We aimed to investigate ROP screening requirements in infants born at more than 30 weeks of gestation
with birth weights above 1250 g in our unit and to compare them with different countries’ screening guidelines to assess
the possible risk of restricted guidelines in our unit.
Materials and methods: Retinopathy screening results were analyzed in relevance to the birth weight, gestational age,
and contributing clinical factors. Infants who had a gestational age of 30 weeks or less and a birth weight less than or equal
to 1250 g (Group 1) were compared to those who had a gestational age greater than 30 weeks and a birth weight greater
than 1250 g (Group 2).
Results: Among 226 live premature infants, 51 (22.5%) of them required laser treatment. No patient developed blindness.
The majority of patients who required laser treatment (n = 27, 53%) belonged to Group 2.
Conclusion: This study showed that applying developed countries’ guidelines might lead to a misdiagnosis of many
patients who require treatment. Restriction criteria in retinopathy screening guidelines should be based on local
population studies of the disease, not on results from other regions like high income countries.
Key words: Premature, retinopathy of prematurity, screening

ROP taraması için kısıtlı evrensel rehberler:
orta gelirli ülkeler için muhtemel bir yanlış yönlendirme
Amaç: Prematüre retinopatisi tarama kriterlerini değerlendiren tüm çalışmaların hedefi tedavi gerektiren retinopati
hastalarını kaçırmadan taranacak hasta sayısını azaltmaktır. Son zamanlarda, özellikle batı ülkelerinden ROP taramasının
tamamlanmış 30 hafta ve doğum ağırlığı 1250 gramdan az olan prematüre bebeklere sınırlanabileceğini öneren çalışmalar
yayınlanmıştır. Bu çalışmada ünitemizdeki >30 hafta üzeri ve >1250 g doğum ağırlığı olan prematüre bebeklerde
retinopati tarama gereksinimi araştırmayı ve elde ettiğimiz sonuçları değişik ülkelerin tarama rehberleri ile karşılaştırmayı
ve kısıtlı tarama programının muhtemel riskini değerlendirmeyi amaçladık.
Yöntem ve gereç: Retinopati tarama sonuçları doğum ağırlığı, gestasyon haftası ve klinik bulgularla bağlantıları açısından
analiz edildi. Gestasyon haftası ≤30 hafta ve doğum ağırlığı ≤1250 g (Grup 1) olan bebekler, gestasyon haftası >30 hafta
ve doğum ağırlığı >1250 g (Grup 2) olan bebekler ile karşılaştırıldı.
Bulgular: 259 prematüre bebeğin 51’inde cerrahi gereksinim tespit edildi ve Evre ≥3 prematüre retinopatisi olan
bebeklerin çoğunluğu (n = 27, % 53) Grup 2’ye aitti. Gelişmiş ülkelerin rehberlerinin uygulanmasının tedavi gerektiren
birçok hastanın tanı alamamasına neden olabileceği görüldü.
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Sonuç: Bu çalışma gelişmiş ülke rehberlerinin uygulanmasının tedavi gerektiren birçok hastanın tanı alamamasına neden
olabileceği göstermiştir. Retinopati tarama kriterlerinin kısıtlanması başka bölgelerden, özellikle de gelişmiş ülkelerden
elde edilen verilere değil, yerel topluluktan elde edilen çalışmalara dayandırılmalıdır.
Anahtar sözcükler: Prematüre, prematüre retinopatisi, tarama

Introduction
Screening of populations at risk of developing a
specific disease or health outcome is a common part
of current medical practice. For screening to be costeffective, the disease has to be worth screening for, the
screening methodology has to be sufficiently effective
to detect those at risk of developing the disease, and
there needs to be an effective treatment for the
disease. Retinopathy of prematurity (ROP) is a disease
that fulfills these requirements; the health outcome to
be avoided is blindness in a premature infant. The cost
effectiveness of avoiding this outcome is immense,
especially in human terms (1,2). Therefore, screening
guidelines for those requiring an ocular examination
that includes all infants at risk is mandatory for
managing ROP. Many studies have evaluated and
proposed criteria for ROP screening. The objective of
all studies was to minimize the number of infants
screened while missing no patients with ROP who
required treatment (3).
The rate of blindness caused by ROP varies greatly
among countries, depending on their level of
development, the availability of evidence-based
neonatal care, the assessment of visual and neonatal
outcomes, and the existence of effective screening and
treatment programs. The population of infants who
develop severe ROP in developed, high income
countries differs from that affected in middle income
countries (4). The American screening guidelines for
ROP, which we have also been using, suggests that
infants of 1500 g of birth weight (BW) or below, or 32
weeks gestational age (GA) or younger, must be
screened, while those infants above 1500 g or older
than 32 weeks should be screened at the discretion of
the attending neonatologist (5). Recently, a few studies
supporting the recommendation that screening for
ROP could be restricted to infants younger than 30
weeks GA with a BW of less than 1250 g have been
reported, especially from Western countries (6-8).
However, with the lack of local outcome data,
application of the new restricted screening guidelines
792

to infants in middle income countries may lead to
misguidance.
In this retrospective study, we sought to find out
whether a BW of less than 1250 g or a GA of less than
30 weeks could provide a safe and efficient screening
criterion for detecting treatable ROP in our neonatal
intensive care unit (NICU) setting. Screening guidelines
recommended previously for developed middle income
and high income countries were reviewed, the
prevalence of ROP that required treatment was defined,
and data were compared with the international
outcomes.
Materials and methods
The study was conducted in a 25-bed, Level III
NICU in Ankara that serves as a referral unit for central
Anatolia, especially for sick, very low birth weight
(VLBW) premature infants. Oxygen saturation targets
were used to set to higher limits (92%-96%) than those
recently accepted (88%-92%), and it was difficult to
keep within those limits because of an insufficient
number of nurses in shifts for ventilated VLBW infants
during the study period (9). The study was approved by
the Ethics Committee and a retrospective review of
NICU computer-based data collection for 6 years (20002005) was undertaken. This study included all of the
premature infants who were screened for ROP. In our
center, infants with a BW of less than 1500 g or a GA of
32 weeks or less, and selected infants with a BW of 15002000 g or a GA of more than 32 weeks with an unstable
clinical course (as defined by the attending
neonatologist) were screened. The first eye examination
was performed at the postnatal age of 3-4 weeks by a
staff ophthalmologist at the bedside. Follow-up was
continued at least every second week until full retinal
vascularization was documented. Infants with
pathological findings were examined more frequently,
depending on the severity of retinal changes. At each
examination, dilation of the pupils was done using
phenylephrine (2.5%) and cyclopentolate (0.5%).

Ö. ERDEVE, B. ATASAY, S. ARSAN, F. BATUOĞLU, H. ATİLLA T. TÜRMEN

Indirect ophthalmoscopy was performed using a 20
D lens and scleral depression. Findings were classified
according to the international classification of ROP
(5). Laser photocoagulation was performed with the
diagnosis of threshold disease.
Patients who required surgery were divided into 2
groups, depending on the BW and GA. Infants who
were less than or equal to 30 weeks of gestation with
a BW equal to or less than 1250 g constituted Group
1, whereas Group 2 included infants born at more
than 30 weeks of gestation with BWs greater than
1250 g. The prevalence of ROP and the clinical
characteristics and perinatal risk factors (BW, GA,
prolonged premature rupture of membranes,
respiratory distress syndrome, mechanical ventilation,
early neonatal sepsis, late neonatal sepsis, patent
ductus arteriosus, and bronchopulmonary dysplasia)
of all of the infants were assessed. The probable
number of missed patients, according to the
application of our NICU’s results to the reported
guidelines and local studies from around the world,
was determined.
Statistical analysis was performed using SPSS
version 12 (SPSS Inc., Chicago, IL, USA). These data
were analyzed using the Mann-Whitney U and chisquare tests. P < 0.05 was considered significant for
all tests.
Results
Of the 259 premature infants who were candidates
for ROP screening, 33 (12.7%) died prior to retinal
examination. Among the 226 VLBW infants who fit
the screening criteria, threshold ROP was detected
and laser photocoagulation was performed in 51
(22.5%) (Figure). The majority of patients with Stage
3 or above ROP belonged to Group 2. Percentages of
infants with prolonged premature rupture of
membranes, early neonatal sepsis, late neonatal sepsis,
and patent ductus arteriosus were as high in Group 1
as in Group 2 (Table 1). The GA of 3 patients in Group
2 was greater than 32 weeks, but none of these patients
had a BW above 1500 g. On the other hand, although
7 patients had BWs greater than 1500 g, all of them
had GAs of 32 weeks or less. When the criteria of a
GA less than or equal to 32 weeks and a BW of less
than or equal to 1500 g were used together, no patient
with Stage 3 or above ROP was missed.

Premature babies requiring screening (n=259)
33 prematures died
Infants eligible for screening (n=226)

ROP Stage ≥ III
(n=51)

Group I
(n=24)

Infants without ROP or
with ROP Stage I -II (n = 175)

Group II
(n=27)

Figure. Number of screened infants and stages of defined
retinopathy of prematurity (ROP).

When the Western guidelines or guidelines
suggested by studies from other countries supporting
the recommendation that screening for ROP could be
restricted to infants with a GA below 30 weeks and a
BW below 1250 g (4,6-8) were applied to our NICU
population, the restriction of ROP screening caused
some of the Stage 3 or above ROP patients to be
missed (Table 2).
Discussion
Improved survival of premature infants has
resulted in an increased incidence of ROP and an
increase in blindness. A recent report showed that the
incidence of ROP-related severe visual impairment or
blindness in middle income countries ranged between
0% and 38.6% (10).
Screening infants at risk is a fundamental first step
in the prevention of blindness. Due to differences in
neonatal care protocols and the socioeconomic status
of each country, the ROP screening criteria followed
in higher income countries might not be appropriate
in middle or low income countries. In addition, infant
health assessment varies among centers within the
same country, leading to intercenter differences in
ROP prevalence rates (11). Recently, the International
NO-ROP group suggested that each country should
adopt its own screening program based on the
characteristics of infants with ROP seen in its own
population (4). Several studies have evaluated and
proposed criteria for ROP screening. The objective of
793
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Table 1. The characteristics and perinatal risk factors of both groups.

Clinical characteristics or risk factors
Mean birth weight (g)
Mean gestational age (weeks)
Sex (male/female)
Prolonged premature rupture of membranes (n, %)
Early neonatal sepsis (n, %)
Late neonatal sepsis (n, %)
Patent ductus arteriosus (n, %)
Respiratory distress syndrome (n, %)
Mechanical ventilation (n, %)
Bronchopulmonary dysplasia (n, %)

Group 1 (n = 24)

Group 2 (n = 27)

P-value

1006 ± 140 (760-1245)
27.4 ± 1.2 (25-30)
11/13
15 (62.5%)
13 (54.2%)
14 (58.3%)
6 (25%)
21 (87.5%)
21 (87.5%)
9 (37.5%)

1358 ± 253 (1260-1780)
31.1 ± 1.3 (30-33)
12/15
18 (66.7%)
12 (44.2%)
16 (59.2%)
8 (29.6%)
12 (44.4%)
14 (51.9%)
2 (7.4%)

<0.001
<0.001
>0.05
>0.05
>0.05
>0.05
>0.05
<0.01
<0.01
<0.01

Table 2. The number of probable missed patients, according to the application of our NICU’s results to the some guidelines and local
studies from around the world (4,6-8,12-16).
Recommendations based on country or study

Criteria for screening

Joint Statement of the AAP, AAPOS, and AAO, 2002
United Kingdom
Sweden
Denmark
Canada
Singapore
Japan
Chile
Brazil and Latin America
India
Argentina
Lithuania
Restricted screening criteria applied to our patients

GA ≤28 weeks or BW ≤1500
GA <32 weeks or BW <1500
GA ≤32 weeks
GA ≤32 weeks or BW ≤1750
GA ≤30 weeks or BW ≤1500
GA <32 weeks or BW <1250
GA <31 weeks or BW <1500
GA <32 weeks or BW <1750
BW <1750
GA <35 weeks or BW <2000
GA ≤32 weeks or BW ≤1500
GA ≤32 weeks or BW ≤1500
GA ≤30 weeks or BW ≤1250

all studies was to minimize the number of infants
screened while missing no patients with ROP who
required treatment (3). Many studies from Western
countries suggested that the criteria of a BW below
1250 g and a GA below 30 weeks could be safely and
efficiently used to screen infants without missing a
diagnosis of sight-threatening ROP (6-8,12).
According to Ho et al., when the new restricted
criteria for screening were applied, 44% of infants
would not have been examined, and this would result
in savings in time, money, and stress to the infants (7).
794

No. of probable
missed patients
7 (13.7%)
4 (7.8%)
3 (5.9%)
0 (0%)
5 (9.8%)
13 (25.4%)
5 (5.9%)
1 (2%)
1 (2%)
0 (0%)
0 (0%)
0 (0%)
27 (52.9%)

Our study revealed that the prevalence of ROP was
very high, and severe ROP was diagnosed among
larger and more mature infants, as well. In our setting,
the criteria of a BW of less than 1250 g and a GA of
less than 30 weeks could not be safely or efficiently
used to screen infants without missing a diagnosis of
sight-threatening ROP. Relatively restricted criteria to
identify premature infants eligible for routine
ophthalmoscopic screening for ROP may result in
some infants going unexamined and their ROP
remaining undetected (Table 2).
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In the USA, screening for ROP is recommended
for infants born with any of the following
characteristics: a BW of less than 1500 g, a GA of 30
weeks or less, or a BW of 1500-2000 g or GA of more
than 30 weeks and an unstable clinical course (5).
Although the BW criterion has not changed, the
recommendations regarding the GA criterion for the
ROP screening of infants was corrected twice in 2006:
in February 2006, the criterion was changed from 28
weeks or less to 32 weeks or less, and in September
2006, a correction of the recommendations decreased
the criterion to 30 weeks or less (5,12). However, only
19% of NICUs in the USA use the currently
recommended GA criterion of 30 weeks; instead, 6%
use a lower, more restrictive criterion, and 74% use a
higher, more inclusive criterion (12).
There are wide variations in screening guidelines
in developing middle income countries and low
income, underdeveloped countries (3,4) (Table 2).
This variation may be the result of a possible lack of
access to advanced neonatal care units in many
developing and underdeveloped countries. We believe
that the higher ROP rate in larger premature infants in
our unit is related to a cumulative ratio due to the
higher chance of survival with advanced gestational
weeks and the liberal use of supplemental oxygen, in
spite of the availability of pulse oximeters at the
bedside.
As in our setting, because larger and more mature
infants
had
developed
threshold
ROP,
ophthalmologists in Latin America suggested
widening the inclusion criteria for diagnostic
screening. In Ecuador, the ROP screening program
started in 1994, and initially only infants with BWs
below 1500 g were examined. The criteria were
changed the following year to less than 1901 g BW
and/or less than 37 weeks GA because several
unexamined infants with BWs greater than 1500 g
presented with inoperable Stage 5 ROP. Since
adoption of the wider criteria, no infant has become
blind from ROP because of screening failure (4). A

recent publication from Thailand supports the
findings of our study: the authors suggested regionspecific criteria of less than 1500 g BW or less than 33
weeks GA (3). Based on our results and data from
developing countries, although the screening criteria
of less than 1500 g or less than 32 weeks seem to be
better, we suggest a regional assessment of patients to
develop optimal screening criteria for ROP.
Even in developed countries in which there is
access to advanced neonatal care units for most, there
is a wide variation in the screening guidelines for ROP
(Table 2) (4,13-17). The purpose of a screening
protocol is to capture all positive instances of the
problem under surveillance, while minimizing the
number of negative exams. The balance of cost versus
benefit to society is one that must be weighed by all
participants. Screening does involve a cost to the
community. The cost to the individual, family, and
community of one child blind from ROP would most
likely be greater than that of the cost saved by reduced
screening (6,8,18). Given the current medical-legal
climate and the liability faced by neonatologists and
pediatricians for ROP screening, there seems to be no
reason for not liberalizing ROP screening guidelines,
at least in Turkey.
Neonatologists serve a central role in coordinating
the care for infants at risk of ROP, but there is lack of
neonatologists in countries like Turkey. Although the
recommendations specify the BW and GA criteria for
ROP screening, they also state that “unit-specific
criteria with respect to BW and GA for examination
for ROP should be established for each NICU by
consultation and agreement between neonatology and
ophthalmology services” (5,12).
We conclude that individual prospective data for
countries or units need to be collected and analyzed to
ascertain screening criteria for ROP. Before applying
international screening criteria to individual settings,
potentially better available and applicable evidencebased care practices and resource provisions should
be sought.
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